Traffic:
10E
10W
15N
15S
57N
57S
60E
60W
210E
210W
This Site
Web Search
powered by
YAHOO! SEARCH
Subscriber Services
|
Home Delivery
|
e-Edition
|
Alerts
|
RSS
Home
News
Ontario
Rancho Cucamonga
Pomona
Upland
Claremont
Montclair
Chino Valley
California
Crime & Public Safety
Elections
Education
S.B. County Watch
Upland Watch
I.E.: Medicare Testing Ground
Sports
Buy Event Tickets Now
Golf - Tee Times and Courses
Preps
Reign Hockey
Rancho Cucamonga Quakes
Local Colleges
USC
UCLA
Lakers
Clippers
Dodgers
Angels
Ducks
Soccer
Motor Sports
Horse Racing
Live Odds
Business
Autos
Real Estate News
Technology
Opinions
Editorial
Letters
Columnists
Blogs
LA.COM
Buy Tickets
Movies
TV
Music
Shopping & Beauty
Recreation
Neighborhood
Arts
Living
Dining
Find A Restaurant
Lottery
Horoscopes
Travel
Trevor's Travels
Health
Crossword Puzzle
Local Casinos
Foothills Magazine
Info
Subscribe For Home Delivery
Contact Us
RSS
Podcast
Subscriber Services
Place An Ad
NIE
Classified
Place an Ad
Homes
Jobs
Auto
Search autos
Buy/Sell a car
Research/Financing a car
Find a dealer
Shopping
This week's ads
Obits
Directories
Local Business
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Amgen
(NQ:
AMGN
)
325.32
+2.59 (+0.80%)
Streaming Delayed Price
Updated: 3:36 PM EDT, Aug 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Amgen
< Previous
1
2
3
4
5
6
7
8
9
...
39
40
Next >
S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
July 03, 2024
The S&P 500 and Nasdaq 100 indices surged to new all-time highs on Thursday, as investors heightened their expectations for rate cuts following June’s sharply lower-than-expected services sector...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
What the Options Market Tells Us About Amgen
July 02, 2024
Via
Benzinga
Amgen Unusual Options Activity
July 01, 2024
Via
Benzinga
1 Dividend Growth Stock to Buy and Hold for 10 Years
June 29, 2024
This company's payouts look safe.
Via
The Motley Fool
10 Blue-Chip Dividend Growth Stocks With 3% Yields And Safe Dividends
June 28, 2024
A look at 10 blue-chip dividend growth stocks with yields above 3%, the opportunity for those yields to continue growing in the future, and where we can be very certain that the dividend is safe.
Via
Talk Markets
Can Amgen Stock Keep Trouncing the S&P 500?
June 27, 2024
Amgen's market-beating ways are unlikely to evaporate any time soon.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Smart Money Is Betting Big In AMGN Options
June 25, 2024
Via
Benzinga
These Are The Best Dow Jones Stocks Of 2024 Thus Far
June 27, 2024
The AI boom helped to produce two best Dow Jones stocks, including newbie Amazon.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Stocks
Exposures
Artificial Intelligence
US Equities
Tech Is Consolidating And The Market’s Seeking New Leadership
June 25, 2024
The tape tells the tale, just like it always does: The tech sector is clearly in consolidation mode right now.
Via
Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
June 24, 2024
Via
Benzinga
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
June 21, 2024
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments.
Via
Benzinga
Where Will Amgen Be in 5 Years?
June 20, 2024
Can Amgen be a market-beating stock?
Via
The Motley Fool
Check Out What Whales Are Doing With AMGN
June 18, 2024
Via
Benzinga
Expert Ratings For Amgen
June 14, 2024
Via
Benzinga
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
June 17, 2024
With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities.
Via
InvestorPlace
Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
June 13, 2024
The companies are closing in on the finish line for two new COPD treatments.
Via
Investor's Business Daily
3 Stocks to Buy as Ozempic Surges in Popularity
June 13, 2024
Ozempic has surged in popularity in recent years, but the best may be to come as innovators look to launch new drugs to meet hot demand.
Via
InvestorPlace
Decoding Amgen's Options Activity: What's the Big Picture?
June 12, 2024
Via
Benzinga
Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club
June 12, 2024
Enthusiasm is growing for a looming approval in COPD treatment.
Via
Investor's Business Daily
Skye Bioscience Pivots To Obesity After Glaucoma Flop; Shares Plummet
June 10, 2024
The company is focusing on obesity treatment after its glaucoma drug failed.
Via
Investor's Business Daily
Market Whales and Their Recent Bets on AMGN Options
June 06, 2024
Via
Benzinga
Here's How Much You Would Have Made Owning Amgen Stock In The Last 20 Years
May 31, 2024
Via
Benzinga
Where Will Amgen Be in 3 Years?
May 29, 2024
The Amgen of 2027 could be much be larger than some investors expect.
Via
The Motley Fool
Is Geron Stock a Buy Following Its First New Drug Approval?
June 08, 2024
Find out if the high-flying biotech stock can keep on climbing higher.
Via
The Motley Fool
Amgen Seeks Expanded US Approval For Autoimmune Disease Drug Acquired Via $28B Horizon Deal
June 05, 2024
Amgen announced Phase 3 trial results for Uplizna for IgG4-related disease, achieving an 87% reduction in flare risk. All key secondary endpoints were met with no new safety signals.
Via
Benzinga
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
June 03, 2024
There's probably a big enough pie here for everyone to get a slice.
Via
The Motley Fool
Amgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca's Drug
May 29, 2024
The FDA has approved Amgen's Bkemv as the first interchangeable biosimilar to AstraZeneca's Soliris for treating rare diseases.
Via
Benzinga
Exposures
Product Safety
OZEM ETF: 7 Things to Know About the New Roundhill GLP-1 & Weight Loss ETF
May 28, 2024
As weight loss drugs are gaining popularity Roundhill GLP 1 And Weight Loss ETF (OZEM) has launched as anew way to invest in them.
Via
InvestorPlace
Topics
ETFs
Amgen's Catching Up to Novo Nordisk and Eli Lilly. Should You Buy It?
May 26, 2024
The gold rush for obesity medications just got a bit more intense.
Via
The Motley Fool
What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday?
May 24, 2024
Verastem Oncology reports promising initial results from the RAMP 205 trial with an 83% ORR for avutometinib and defactinib in metastatic pancreatic cancer. FDA submission for recurrent KRAS mutant...
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
...
39
40
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Privacy Policy
|
Terms of Use
|
MNG Corporate Site Map
|
Copyright